Correction: Improved anti-tumor efficacy via combination of oxaliplatin and fibrin glue in colorectal cancer

Yuzhu Hu; Ting Yu; Xiaoxiao Liu; Yihong He; Lihong Deng; Jiajuan Guo; Yuanqi Hua; Ting Luo; Xiang Gao

doi:10.18632/oncotarget.27605

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Corrections:

Correction: Improved anti-tumor efficacy via combination of oxaliplatin and fibrin glue in colorectal cancer

PDF | How to cite

Oncotarget. 2020; 11:3484-3485. https://doi.org/10.18632/oncotarget.27605

Metrics: PDF 972 views | ?

Yuzhu Hu¹, Ting Yu¹, Xiaoxiao Liu¹, Yihong He¹, Lihong Deng¹, Jiajuan Guo¹, Yuanqi Hua¹, Ting Luo¹ and Xiang Gao²

¹ Department of Head & Neck and Mammary Oncology and Department of Medical Oncology, Cancer Center, State Key Laboratory of Biotherapy, Laboratory of Molecular Diagnosis of Cancer, West China Hospital, West China Medical School, Sichuan University, Chengdu 610041, PR China
² Department of Neurosurgery and Institute of Neurosurgery, State Key Laboratory of Biotherapy/Collaborative Innovation Center for Biotherapy, West China Hospital, West China Medical School, Sichuan University, Chengdu 610041, PR China

Published: September 15, 2020

This article has been corrected: Due to mistakes during the assembly of Figure 8, the CD31 immunohistochemical images for the NS and FG groups are incorrect. The corrected Figure 8, using the proper images obtained from the original data, is shown below. The authors declare that these corrections do not change the results or conclusions of this paper.

Original article: Oncotarget. 2018; 9:2515–2526. DOI: https://doi.org/10.18632/oncotarget.23507.

Figure 8: OXP and FG combination repressed tumor angiogenesis CD31 staining can be used to label microvessel in tumor sections. Results showed reduced microvessel densities (MVD) of tumor cells in OXP group, compared with that in NS group and FG group (P < 0.0001, OXP group versus NS group and FG group.). There were less microvessels in OXP + FG group than that in OXP group (P < 0.001, OXP + FG group versus OXP group). Representative images of each group were showed above.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 27605

Publication Alerts

Corrections:

Correction: Improved anti-tumor efficacy via combination of oxaliplatin and fibrin glue in colorectal cancer